Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence



In response to tenacious stress signals, such as the unscheduled activation of oncogenes, cells can mobilize tumour suppressor networks to avert the hazard of malignant transformation. A large body of evidence indicates that oncogene-induced senescence (OIS) acts as such a break, withdrawing cells from the proliferative pool almost irreversibly, thus crafting a vital pathophysiological mechanism that protects against cancer1,2,3,4,5. Despite the widespread contribution of OIS to the cessation of tumorigenic expansion in animal models and humans, we have only just begun to define the underlying mechanism and identify key players6. Although deregulation of metabolism is intimately linked to the proliferative capacity of cells7,8,9,10, and senescent cells are thought to remain metabolically active11, little has been investigated in detail about the role of cellular metabolism in OIS. Here we show, by metabolic profiling and functional perturbations, that the mitochondrial gatekeeper pyruvate dehydrogenase (PDH) is a crucial mediator of senescence induced by BRAFV600E, an oncogene commonly mutated in melanoma and other cancers. BRAFV600E-induced senescence was accompanied by simultaneous suppression of the PDH-inhibitory enzyme pyruvate dehydrogenase kinase 1 (PDK1) and induction of the PDH-activating enzyme pyruvate dehydrogenase phosphatase 2 (PDP2). The resulting combined activation of PDH enhanced the use of pyruvate in the tricarboxylic acid cycle, causing increased respiration and redox stress. Abrogation of OIS, a rate-limiting step towards oncogenic transformation, coincided with reversion of these processes. Further supporting a crucial role of PDH in OIS, enforced normalization of either PDK1 or PDP2 expression levels inhibited PDH and abrogated OIS, thereby licensing BRAFV600E-driven melanoma development. Finally, depletion of PDK1 eradicated melanoma subpopulations resistant to targeted BRAF inhibition, and caused regression of established melanomas. These results reveal a mechanistic relationship between OIS and a key metabolic signalling axis, which may be exploited therapeutically.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: The PDK1–PDP2–PDH axis is deregulated in OIS.
Figure 2: PDP2 regulates metabolic rewiring and OIS.
Figure 3: PDK1 regulates metabolic rewiring and OIS, and acts tumorigenically.
Figure 4: PDK1 depletion causes melanoma regression and eradicates subpopulations resistant to targeted BRAFV600E inhibition.


  1. Campisi, J. Suppressing cancer: the importance of being senescent. Science 309, 886–887 (2005)

    Article  CAS  Google Scholar 

  2. Collado, M. & Serrano, M. Senescence in tumours: evidence from mice and humans. Nature Rev. Cancer 10, 51–57 (2010)

    Article  CAS  Google Scholar 

  3. Vredeveld, L. C. W. et al. Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev. 26, 1055–1069 (2012)

    Article  CAS  Google Scholar 

  4. Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of senescence. Genes Dev. 24, 2463–2479 (2010)

    Article  CAS  Google Scholar 

  5. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307–315 (2004)

    Article  ADS  CAS  Google Scholar 

  6. Adams, P. D. Healing and hurting: molecular mechanisms, functions, and pathologies of cellular senescence. Mol. Cell 36, 2–14 (2009)

    Article  CAS  Google Scholar 

  7. DeBerardinis, R. J., Sayed, N., Ditsworth, D. & Thompson, C. B. Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev. 18, 54–61 (2008)

    Article  CAS  Google Scholar 

  8. Tennant, D. A., Durán, R. V. & Gottlieb, E. Targeting metabolic transformation for cancer therapy. Nature Rev. Cancer 10, 267–277 (2010)

    Article  CAS  Google Scholar 

  9. Wellen, K. E. & Thompson, C. B. Cellular metabolic stress: considering how cells respond to nutrient excess. Mol. Cell 40, 323–332 (2010)

    Article  CAS  Google Scholar 

  10. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009)

    Article  ADS  CAS  Google Scholar 

  11. Campisi, J. Replicative senescence: an old lives’ tale? Cell 84, 497–500 (1996)

    Article  CAS  Google Scholar 

  12. Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005)

    Article  ADS  CAS  Google Scholar 

  13. Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008)

    Article  CAS  Google Scholar 

  14. Dankort, D. et al. BrafV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genet. 41, 544–552 (2009)

    Article  CAS  Google Scholar 

  15. Dhomen, N. et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294–303 (2009)

    Article  CAS  Google Scholar 

  16. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002)

    Article  ADS  CAS  Google Scholar 

  17. Wieland, O. H. The mammalian pyruvate dehydrogenase complex: structure and regulation. Rev. Physiol. Biochem. Pharmacol. 96, 123–170 (1983)

    Article  CAS  Google Scholar 

  18. Patel, M. S. & Roche, T. E. Molecular biology and biochemistry of pyruvate dehydrogenase complexes. FASEB J. 4, 3224–3233 (1990)

    Article  CAS  Google Scholar 

  19. Kolobova, E., Tuganova, A., Boulatnikov, I. & Popov, K. M. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem. J. 358, 69–77 (2001)

    Article  CAS  Google Scholar 

  20. Roche, T. E. et al. Distinct regulatory properties of pyruvate dehydrogenase kinase and phosphatase isoforms. Prog. Nucleic Acid Res. Mol. Biol. 70, 33–75 (2001)

    Article  CAS  Google Scholar 

  21. Holness, M. J. & Sugden, M. C. Regulation of pyruvate dehydrogenase complex activity by reversible phosphorylation. Biochem. Soc. Trans. 31, 1143–1151 (2003)

    Article  CAS  Google Scholar 

  22. Patel, M. S. & Korotchkina, L. G. Regulation of the pyruvate dehydrogenase complex. Biochem. Soc. Trans. 34, 217–222 (2006)

    Article  CAS  Google Scholar 

  23. Lemons, J. M. S. et al. Quiescent fibroblasts exhibit high metabolic activity. PLoS Biol. 8, e1000514 (2010)

    Article  Google Scholar 

  24. Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425–434 (2006)

    Article  CAS  Google Scholar 

  25. Mooi, W. J. & Peeper, D. S. Oncogene-induced cell senescence–halting on the road to cancer. N. Engl. J. Med. 355, 1037–1046 (2006)

    Article  CAS  Google Scholar 

  26. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041–3046 (2008)

    Article  ADS  CAS  Google Scholar 

  27. Flaherty, K. T., Yasothan, U. & Kirkpatrick, P. Vemurafenib. Nature Rev. Drug Discov. 10, 811–812 (2011)

    Article  CAS  Google Scholar 

  28. Frezza, C. et al. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477, 225–228 (2011)

    Article  ADS  CAS  Google Scholar 

  29. Frezza, C. et al. Metabolic profiling of hypoxic cells revealed a catabolic signature required for cell survival. PLoS ONE 6, e24411 (2011)

    Article  ADS  CAS  Google Scholar 

  30. Chaneton, B. et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491, 458–462 (2012)

    Article  ADS  CAS  Google Scholar 

  31. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997)

    Article  CAS  Google Scholar 

  32. Sviderskaya, E. V. et al. Complementation of hypopigmentation in p-mutant (pink-eyed dilution) mouse melanocytes by normal human P cDNA, and defective complementation by OCA2 mutant sequences. J. Invest. Dermatol. 108, 30–34 (1997)

    Article  CAS  Google Scholar 

  33. Dankort, D. et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379–384 (2007)

    Article  CAS  Google Scholar 

Download references


We thank J.-Y. Song for pathological analysis, M. McMahon for providing BrafCA mice, C. Vogel for sharing cell lines, R. van Amerongen for critical reading of the manuscript, and all members of the Gottlieb and Peeper laboratories for their input. This work was supported by Cancer Research UK, Spanish Government-EU-FEDER (grants SAF2011-25726 and ISCIII-RTICC-RD6/0020/0046) and ICREA-Academia to M.C., Israel Cancer Research Foundation and Israel Science Foundation to T.S., a Vici grant from the Netherlands Organization for Scientific Research (NWO) and a Queen Wilhelmina Award grant from the Dutch Cancer Society (KWF Kankerbestrijding) to D.S.P.

Author information

Authors and Affiliations



J.K., E.G. and D.S.P. conceived the project, analysed the data and wrote the manuscript. J.K. performed all in vitro experiments and carried out the in vivo experiments together with K.M. J.K., K.M. and B.C. performed metabolic experiments. L.Z. and G.M. performed LC–MS analyses. S.H.B. and E.M.E.V. provided low passage melanoma cell lines. V.A.S., M.C. and T.S. helped with metabolic analyses. All authors discussed the results and commented on the manuscript. E.G. and D.S.P. contributed equally to this work.

Corresponding authors

Correspondence to Eyal Gottlieb or Daniel S. Peeper.

Ethics declarations

Competing interests

A patent application for combined PDK and MAPK/ERK pathway inhibition in neoplasia has been filed, with J.K. and D.S.P. as inventors.

Supplementary information

Supplementary Figures

This file contains Supplementary Figures 1-15. (PDF 4632 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kaplon, J., Zheng, L., Meissl, K. et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498, 109–112 (2013).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer